{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_11",
        "affectedSection": "Section 1.3 - Schedule of Activities (SoA)",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Addition of Week 3 visit header and associated footnote."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_11",
        "affectedSection": "Section 10.6 - Appendix 6: Liver and other safety",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Incorporation of liver function test monitoring guidance previously held in the study manual."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_11",
        "affectedSection": "Section 10.8 - Appendix 8A: Drug Metabolism",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updates to co-medication guidance and metabolic interaction references."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_11",
        "affectedSection": "Section 10.11.4 - Country-specific provisions",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "New section for US, Brazil, and Israel regarding FDA partial clinical hold conditions and prohibited inhibitors."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_11",
        "affectedSection": "Throughout Document",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Reformatting, editorial changes, and updates to table of contents and abbreviations."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_11",
        "reasonText": "Include liver function test monitoring guidance previously in the study manual",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_11",
        "reasonText": "Update co-medication guidance as per Health Authority request",
        "category": "Regulatory",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_11",
        "reasonText": "Correction of error regarding modafinil classification as a weak rather than moderate CYP3A inducer",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_11",
        "reasonText": "Updated guidance for CYP inhibitors/inducers based on information from DDI study",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_11",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "Week 3 added in the visit header and in footnote ‘l’",
        "summary": "Added Week 3 visit to the Schedule of Activities."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_11",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "10.8",
        "beforeText": "Reference to www.druginteractioninfo.org",
        "afterText": "Recommendation for the sites to refer to the drug label for metabolic interactions",
        "summary": "Removed external website reference for drug interactions."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_11",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "10.8",
        "beforeText": "modafinil in the list of moderate CYP3A inducers",
        "afterText": "modafinil removed from the list",
        "summary": "Removed modafinil from prohibited list as it is a weak inducer."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_11",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "10.8",
        "beforeText": "rifabutin in the list of potent CYP3A inducers",
        "afterText": "rifabutin moved to the list of moderate CYP3A inducers",
        "summary": "Reclassified rifabutin based on DDI study data."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_11",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "10.11.4",
        "afterText": "Prohibited use of CYP3A and CYP2C8 inhibitors and restriction of grapefruit/grapefruit juice",
        "summary": "Added specific restrictions for sites following FDA partial clinical hold."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 4,
      "changeCount": 5
    }
  }
}